PT1699784E - Novos derivados de oxazolidinona - Google Patents

Novos derivados de oxazolidinona Download PDF

Info

Publication number
PT1699784E
PT1699784E PT04808458T PT04808458T PT1699784E PT 1699784 E PT1699784 E PT 1699784E PT 04808458 T PT04808458 T PT 04808458T PT 04808458 T PT04808458 T PT 04808458T PT 1699784 E PT1699784 E PT 1699784E
Authority
PT
Portugal
Prior art keywords
derivatives
oxazolidinone
present
antibiotic
bacteria
Prior art date
Application number
PT04808458T
Other languages
English (en)
Portuguese (pt)
Inventor
Jae Keol Rhee
Weon Bin Im
Chong Hwan Cho
Sung Hak Choi
Tae Ho Lee
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36660051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1699784(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of PT1699784E publication Critical patent/PT1699784E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT04808458T 2003-12-18 2004-12-17 Novos derivados de oxazolidinona PT1699784E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030093342 2003-12-18
KR1020040058809A KR100854211B1 (ko) 2003-12-18 2004-07-27 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물

Publications (1)

Publication Number Publication Date
PT1699784E true PT1699784E (pt) 2011-10-06

Family

ID=36660051

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04808458T PT1699784E (pt) 2003-12-18 2004-12-17 Novos derivados de oxazolidinona

Country Status (25)

Country Link
US (9) US7816379B2 (enExample)
EP (2) EP2305657B1 (enExample)
JP (1) JP4739229B2 (enExample)
KR (1) KR100854211B1 (enExample)
CN (4) CN102702184B (enExample)
AT (1) ATE514686T1 (enExample)
AU (2) AU2004299413C1 (enExample)
BE (1) BE2015C050I2 (enExample)
BR (1) BRPI0417800B8 (enExample)
CA (1) CA2549062C (enExample)
CY (2) CY1112445T1 (enExample)
DK (1) DK1699784T3 (enExample)
ES (1) ES2391820T3 (enExample)
FR (1) FR15C0062I2 (enExample)
HU (1) HUS1500046I1 (enExample)
LT (1) LTC1699784I2 (enExample)
LU (1) LU92834I2 (enExample)
MX (2) MX339597B (enExample)
NL (1) NL300759I1 (enExample)
NZ (2) NZ547928A (enExample)
PL (1) PL1699784T3 (enExample)
PT (1) PT1699784E (enExample)
RU (2) RU2559620C2 (enExample)
SI (1) SI1699784T1 (enExample)
WO (1) WO2005058886A1 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
ES2393292T3 (es) 2003-06-03 2012-12-20 Rib-X Pharmaceuticals, Inc. Compuestos heterocíclicos de biarilo y métodos de obtención y uso de los mismos
US7129259B2 (en) 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
MXPA06013540A (es) * 2004-05-25 2007-01-26 Astrazeneca Ab Derivados de 3-(4-(2 -dihidroisoxasol -3-ilpiridin-5-il) fenil)-5- triazol-1- ilmetiloxazolidin -2-ona como inhibidores de mao para el tratamiento de infecciones bacterianas.
EP1799677A1 (en) * 2004-10-08 2007-06-27 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
JP5534497B2 (ja) 2005-06-08 2014-07-02 メリンタ セラピューティクス，インコーポレイテッド トリアゾール類の合成方法
CN100406455C (zh) * 2006-02-20 2008-07-30 中国科学院上海药物研究所 含三氮唑基的噁唑烷酮类化合物及其制备方法和用途
US8124623B2 (en) 2006-11-10 2012-02-28 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
MY148847A (en) * 2006-11-10 2013-06-14 Actelion Pharmaceuticals Ltd 5-hydroxymethyl-oxazolidin-2-one derivatives
CN102014903B (zh) * 2008-05-09 2013-07-10 埃科特莱茵药品有限公司 用于治疗细菌性肠疾病的5-羟基甲基-*唑烷-2-酮衍生物
WO2010047737A2 (en) 2008-09-02 2010-04-29 Micurx Pharmaceuticals, Inc. Antimicrobial indoline compounds for treatment of bacterial infections
CA2738671C (en) * 2008-10-10 2018-05-01 Trius Therapeutics, Inc. Methods for preparing oxazolidinones and compositions containing them
PE20120029A1 (es) 2008-11-15 2012-02-13 Rib X Pharmaceuticals Inc Composiciones antimicrobianas
CN102224151A (zh) 2008-11-20 2011-10-19 万能药生物有限公司 新的抗微生物剂
WO2010061908A1 (ja) 2008-11-28 2010-06-03 中外製薬株式会社 １－（２ｈ）－イソキノロン誘導体
AP2987A (en) 2009-02-03 2014-09-30 Trius Therapeutics Crystalline form of (R)-3-(-4(2-(2-methyltetrazol-5-YL)pyridin-5-YL)-3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one dihydrogen phosphate
CN101798302B (zh) 2009-02-06 2014-11-05 上海盟科药业有限公司 抗生素类药物1-(邻-氟苯基)二氢吡啶酮的合成及生产的方法和工艺
JP5731413B2 (ja) * 2009-03-13 2015-06-10 サン ケミカル ベスローテン フェンノートシャップ エネルギー硬化性組成物に有用な環式カルバメート化合物
US8580767B2 (en) * 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
US8906913B2 (en) 2009-06-26 2014-12-09 Panacea Biotec Limited Azabicyclohexanes
EA022765B1 (ru) * 2009-10-13 2016-02-29 Мелинта Терапьютикс, Инк. Фармацевтическая композиция
IT1397023B1 (it) 2009-11-27 2012-12-20 Professional Dietetics Srl Composizioni comprendenti amminoacidi, per il trattamento della broncopneumopatia cronica ostruttiva
ES2368236B1 (es) * 2009-12-23 2012-09-26 Merck Sharp & Dohme Corp. Agentes antibacterianos.
CN102276595A (zh) * 2010-04-16 2011-12-14 山东轩竹医药科技有限公司 含有五元杂环的噁唑烷酮抗菌素
KR101180174B1 (ko) 2010-04-23 2012-09-05 동아제약주식회사 신규한 벤즈아미드 유도체
WO2012033952A1 (en) 2010-09-10 2012-03-15 Micurx Pharmaceuticals, Inc. 3 - phenyl- 2 -oxo- 1, 3 -oxazolidines for treatment of bacterial infections
JP5902188B2 (ja) 2010-11-01 2016-04-13 メリンタ セラピューティクス，インコーポレイテッド 薬学的組成物
NZ610638A (en) 2010-11-24 2015-05-29 Melinta Therapeutics Inc Pharmaceutical compositions comprising radezolid
CN103415511B (zh) * 2011-01-31 2016-01-20 国立大学法人长崎大学 光学活性化合物或其盐的制造方法
KR101653570B1 (ko) * 2011-03-30 2016-09-02 주식회사 레고켐 바이오사이언스 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
EP2762479A4 (en) 2011-09-29 2015-04-22 Xuanzhu Pharma Co Ltd OXAZOLIDINONE ANTIBACTERIAL MEDICINE BASED ON BIARYLIC HETEROCYCLE SUBSTITUTED
WO2013059610A1 (en) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
CN103896963B (zh) * 2012-12-26 2017-06-09 中国科学院上海药物研究所 苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
HK1219690A1 (zh) 2013-03-15 2017-04-13 Melinta Subsidiary Corp. 利用抗生素来治疗超重和肥胖患者感染的方法
KR101480982B1 (ko) * 2013-03-20 2015-02-03 (주)셀인바이오 골형성 유도 화합물 및 이의 응용
CN104650142B (zh) * 2013-11-25 2018-06-22 山东新时代药业有限公司 一种福沙匹坦二甲葡胺的制备方法
WO2015127316A1 (en) 2014-02-21 2015-08-27 Micurx Pharmaceuticals, Inc. Water-soluble o-carbonyl phosphoramidate prodrugs for therapeutic administration
CN105229001B (zh) * 2014-04-18 2017-04-26 杭州普晒医药科技有限公司 一种噁唑烷酮类抗生素的晶型及制备方法、组合物和用途
KR101597327B1 (ko) * 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
WO2016009401A2 (en) * 2014-07-18 2016-01-21 Dr. Reddy's Laboratories Limited Preparation of tedizolid phosphate
CN105566392B (zh) * 2014-10-15 2018-12-21 正大天晴药业集团股份有限公司 一种细菌蛋白质合成抑制剂的制备方法
CN105418678B (zh) * 2014-09-17 2018-11-20 正大天晴药业集团股份有限公司 一种磷酸特地唑胺的制备方法
WO2016041505A1 (zh) * 2014-09-17 2016-03-24 正大天晴药业集团股份有限公司 一种磷酸特地唑胺、其中间体以及它们的制备方法
CN105837633B (zh) * 2015-01-12 2018-11-20 正大天晴药业集团股份有限公司 一种抗菌化合物的制备方法
CN105503955B (zh) * 2014-10-15 2018-11-20 正大天晴药业集团股份有限公司 一种抗革兰氏阳性菌的化合物的制备方法
CN104496979A (zh) * 2014-09-17 2015-04-08 博瑞生物医药技术(苏州)有限公司 一种噁唑烷酮类化合物及其中间体的制备方法
CN104327119A (zh) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 磷酸泰地唑胺的制备方法
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents
WO2016088103A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited A process for the preparation of tedizolid phosphate
WO2016088101A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
WO2016088100A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
CN104530128B (zh) * 2014-12-30 2016-08-24 石药集团中诺药业（石家庄）有限公司 一种磷酸特地唑胺二钠盐及其制备方法
CN104558034A (zh) * 2015-01-21 2015-04-29 齐鲁制药有限公司 磷酸特地唑胺二钠盐的新晶型及其制备方法
CN105859780A (zh) * 2015-01-21 2016-08-17 山东康美乐医药科技有限公司 磷酸特地唑胺的制备方法
CN104610359B (zh) * 2015-01-26 2017-07-14 成都新恒创药业有限公司 一种制备磷酸特地唑胺的关键中间体及其制备方法
CN105837634B (zh) * 2015-01-30 2020-09-04 上海创诺制药有限公司 一种泰地唑胺磷酸酯结晶体及其制备方法
CN104592218B (zh) * 2015-02-13 2015-11-04 江苏欧信医药化工有限公司 一种泰地唑胺的合成方法
CN106146558A (zh) * 2015-04-10 2016-11-23 博瑞生物医药（苏州）股份有限公司 新的噁唑烷酮类化合物及其制备方法
CN110078764B (zh) * 2015-04-10 2021-10-26 博瑞生物医药（苏州）股份有限公司 一种噁唑烷酮类化合物的制备方法
CN106279281B (zh) * 2015-05-15 2018-08-03 重庆圣华曦药业股份有限公司 噁唑烷酮类抗菌素泰地唑胺磷酸酯的精制方法
CN106317114B (zh) * 2015-07-02 2018-11-20 南京优科制药有限公司 一种磷酸特地唑胺的制备方法
CN106632298B (zh) * 2015-11-03 2021-06-01 上海科胜药物研发有限公司 一种泰地唑胺的制备方法及其中间体
KR101855334B1 (ko) * 2015-12-11 2018-06-08 에스티팜 주식회사 옥사졸리디논 유도체의 중간체 제조방법
CN105496976A (zh) * 2015-12-18 2016-04-20 北京万全德众医药生物技术有限公司 一种磷酸特地唑胺片及其制备方法
CN105949278B (zh) * 2016-03-30 2019-12-06 南京曼杰生物科技有限公司 一种取代的四氢呋喃水溶性衍生物及其应用
CN106083994B (zh) * 2016-04-18 2019-12-06 南京曼杰生物科技有限公司 取代的噁唑烷酮水溶性衍生物及其应用
CN108368139B (zh) * 2016-04-22 2020-12-18 深圳市塔吉瑞生物医药有限公司 取代的恶唑烷酮化合物及其应用
CN107400126A (zh) * 2016-05-19 2017-11-28 陕西合成药业股份有限公司 新型噁唑烷酮类化合物及其制备方法和在医学上的应用
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN106632240A (zh) * 2016-11-25 2017-05-10 山东轩德医药科技有限公司 一种2‑甲基‑5‑(5‑溴吡啶‑2‑基)四氮唑的制备方法
US10087171B2 (en) 2016-12-19 2018-10-02 Actelion Pharmaceuticals Ltd Crystalline forms of cadazolid
CN107226825B (zh) * 2017-06-14 2019-08-02 浙江海正药业股份有限公司 磷酸泰地唑胺铵盐及其晶型、制备方法和医药用途
WO2019118311A1 (en) 2017-12-13 2019-06-20 Merck Sharp & Dohme Corp. Pharmaceutical compositions of tedizolid phosphate
CN110804038B (zh) * 2018-08-06 2021-03-05 上海博志研新药物技术有限公司 磷酸特地唑胺及其中间体的制备方法
US12365656B2 (en) 2019-01-18 2025-07-22 Merck Sharp & Dohme Llc Oxazolidinone compounds and methods of use thereof as antibacterial agents
WO2021000297A1 (en) 2019-07-03 2021-01-07 Merck Sharp & Dohme Corp. Compounds and methods of use thereof as antibacterial agents
CN112940038A (zh) * 2019-12-11 2021-06-11 华创合成制药股份有限公司 新型噁唑烷酮类化合物及其制备方法
CN111116551B (zh) * 2020-01-03 2022-05-20 中国医科大学 1-氮杂螺[5.5]十一烷-3-酮类及1-氮杂螺[5.5]十一烷-3-醇类化合物
WO2021258013A1 (en) * 2020-06-18 2021-12-23 Akagera Medicines, Inc. Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
EP4168000A4 (en) * 2020-06-18 2024-06-26 Akagera Medicines, Inc. OXAZOLIDINONE-LIKE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE-LIKE COMPOUNDS AND RELATED METHODS OF USE
CN114315897B (zh) * 2020-09-30 2024-05-17 北京澳合药物研究院有限公司 一种磷酸特地唑胺新晶体及其制备方法
KR20230124927A (ko) 2020-11-25 2023-08-28 아카제라 메디신즈, 인크. 핵산 전달을 위한 지질 나노입자, 및 관련 사용 방법
CN112500433A (zh) * 2020-12-23 2021-03-16 桂林南药股份有限公司 一种磷酸特地唑胺的制备方法
CN113197874B (zh) * 2021-04-28 2023-05-26 北京福元医药股份有限公司 一种磷酸特地唑胺口服固体制剂
AU2022420614A1 (en) * 2021-12-22 2024-06-27 Akagera Medicines, Inc. Oxazolidinone liposome compositions
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4340606A (en) * 1980-10-23 1982-07-20 E. I. Du Pont De Nemours And Company 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
FR2500450A1 (fr) 1981-02-25 1982-08-27 Delalande Sa Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique
US4461773A (en) 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
CA1320730C (en) 1987-10-16 1993-07-27 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
EP0610265B1 (en) 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
RU2119484C1 (ru) * 1992-12-08 1998-09-27 Дзе Апджон Компани Тропонзамещенный фенилоксазолидинон или его фармацевтически приемлемые соли или гидраты
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
NZ274966A (en) 1993-11-22 1998-01-26 Upjohn Co Substituted-hydroxyacetyl piperazine phenyl oxazolidinone derivatives, use in pharmaceutical compositions
DK0856002T3 (da) * 1995-09-01 2002-02-11 Upjohn Co Phenyloxazolidinoner med en C-C-binding til 4-8 ledede heterocycliske ringe
GB9702213D0 (en) 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
JP2002513424A (ja) 1997-07-11 2002-05-08 ファルマシア・アンド・アップジョン・カンパニー チアジアゾリルおよびオキサジアゾリルフェニルオキサゾリジノン抗菌剤
IL136062A (en) * 1997-11-12 2004-02-08 Upjohn Co History of xahydro - 5-oxo- (1, 4 diazepine-1-yl) phenyl oxazolidinone and pharmaceutical preparations containing them
CA2327100A1 (en) * 1998-05-18 1999-11-25 Pharmacia & Upjohn Company Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
US6689779B2 (en) 2000-06-05 2004-02-10 Dong A Pharm. Co., Ltd. Oxazolidinone derivatives and a process for the preparation thereof
KR100731469B1 (ko) * 2000-06-05 2007-06-21 동아제약주식회사 피리딘 고리를 포함하는 옥사졸리디논 유도체 및 그의제조방법
KR100713170B1 (ko) * 2001-03-07 2007-05-02 동아제약주식회사 헤테로고리 또는 헤테로아로마틱 고리가 치환된 피리딘고리를 포함하는 옥사졸리디논 유도체 및 그의 제조방법
US20020115669A1 (en) 2000-08-31 2002-08-22 Wiedeman Paul E. Oxazolidinone chemotherapeutic agents
YU52403A (sh) 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
US20050032861A1 (en) 2001-04-07 2005-02-10 Betts Michael John Oxazolidines containing a sulfonimid group as antibiotics
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7396847B2 (en) 2001-09-11 2008-07-08 Astrazeneca Ab Oxazolidinone and/or isoxazoline as antibacterial agents
US20050043374A1 (en) 2001-10-25 2005-02-24 Gravestock Michael Barry Aryl substituted oxazolidinones with antibacterial activity
NZ515881A (en) 2001-12-03 2004-09-24 New Zealand Dairy Board Cheese flavour ingredient and method of its production
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
RU2004129278A (ru) 2002-02-28 2005-06-10 Астразенека Аб (Se) Химические соединения
RU2004129276A (ru) 2002-02-28 2005-06-10 Астразенека Аб (Se) Производные 3-циклического-5-(азотсодержащего 5-членного кольцевого) метил-оксазолидинона и их применение в качестве антибактериальных средств
JP2006508192A (ja) 2002-11-28 2006-03-09 アストラゼネカ アクチボラグ 抗細菌薬としてのオキサゾリジノンおよび／またはイソオキサゾリン誘導体
CA2507628A1 (en) * 2002-11-28 2004-06-10 Astrazeneca Ab Oxazolidinones as antibacterial agents
GB0229518D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
TW200500360A (en) 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
GB0306358D0 (en) 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
NZ544237A (en) * 2003-07-02 2008-09-26 Merck & Co Inc Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
US20070185132A1 (en) * 2003-07-02 2007-08-09 Yasumichi Fukuda Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo
WO2005051933A1 (en) 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
US7129259B2 (en) * 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
GB0411596D0 (en) 2004-05-25 2004-06-30 Astrazeneca Ab Chemical process
BRPI0511526A (pt) 2004-05-25 2007-12-26 Astrazeneca Ab composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
US20080064689A1 (en) 2004-05-25 2008-03-13 Astrazeneca Ab 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
MXPA06013540A (es) 2004-05-25 2007-01-26 Astrazeneca Ab Derivados de 3-(4-(2 -dihidroisoxasol -3-ilpiridin-5-il) fenil)-5- triazol-1- ilmetiloxazolidin -2-ona como inhibidores de mao para el tratamiento de infecciones bacterianas.
CA2567929A1 (en) 2004-05-25 2005-12-08 Astrazeneca Ab 3- {4- (pyridin-3-yl) phenyl} -5- (1h-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents
EP1799677A1 (en) 2004-10-08 2007-06-27 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
EP1912980A2 (en) 2005-06-20 2008-04-23 Wockhardt Limited Oxazolidinones bearing antimicrobial activity composition and methods of preparation
WO2007138381A2 (en) 2005-10-14 2007-12-06 Targanta Therapeutics Inc. Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections
WO2009020616A1 (en) 2007-08-06 2009-02-12 Micurx Pharmaceuticals, Inc. Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections
CA2738671C (en) 2008-10-10 2018-05-01 Trius Therapeutics, Inc. Methods for preparing oxazolidinones and compositions containing them
AP2987A (en) 2009-02-03 2014-09-30 Trius Therapeutics Crystalline form of (R)-3-(-4(2-(2-methyltetrazol-5-YL)pyridin-5-YL)-3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one dihydrogen phosphate
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use

Also Published As

Publication number Publication date
EP2305657A2 (en) 2011-04-06
KR100854211B1 (ko) 2008-08-26
SI1699784T1 (sl) 2011-11-30
US20140350059A1 (en) 2014-11-27
US7816379B2 (en) 2010-10-19
AU2009200606B2 (en) 2011-01-06
US20070155798A1 (en) 2007-07-05
EP1699784B1 (en) 2011-06-29
US20170049763A1 (en) 2017-02-23
KR20050061271A (ko) 2005-06-22
BRPI0417800A (pt) 2007-04-10
BRPI0417800B1 (pt) 2019-10-08
NZ575842A (en) 2010-10-29
JP2007514737A (ja) 2007-06-07
MX339597B (es) 2016-06-01
CN102702184B (zh) 2016-06-08
BE2015C050I2 (enExample) 2024-08-08
US9163043B2 (en) 2015-10-20
DK1699784T3 (da) 2011-10-10
US8420676B2 (en) 2013-04-16
AU2009200606A1 (en) 2009-03-05
NL300759I2 (enExample) 2015-12-22
CN101982468B (zh) 2012-02-08
EP2305657A3 (en) 2011-04-27
AU2004299413B2 (en) 2008-11-20
CN102516238A (zh) 2012-06-27
US20090192197A1 (en) 2009-07-30
ES2391820T3 (es) 2012-11-30
RU2559620C2 (ru) 2015-08-10
NL300759I1 (enExample) 2015-12-22
US20170333414A1 (en) 2017-11-23
US20200078345A1 (en) 2020-03-12
HK1153738A1 (en) 2012-04-05
LU92834I2 (fr) 2015-11-17
CN1894242B (zh) 2012-07-04
PL1699784T3 (pl) 2011-11-30
WO2005058886A1 (en) 2005-06-30
CN1894242A (zh) 2007-01-10
CY2015036I2 (el) 2016-06-22
EP1699784A1 (en) 2006-09-13
US20210121449A1 (en) 2021-04-29
RU2414469C2 (ru) 2011-03-20
EP2305657B1 (en) 2012-08-22
EP1699784A4 (en) 2008-09-03
AU2004299413A1 (en) 2005-06-30
CN102702184A (zh) 2012-10-03
RU2414469C3 (ru) 2017-06-14
CA2549062A1 (en) 2005-06-30
NZ547928A (en) 2009-05-31
CN101982468A (zh) 2011-03-02
RU2010149618A (ru) 2012-06-27
RU2006125761A (ru) 2008-01-27
US20180344716A1 (en) 2018-12-06
MXPA06006955A (es) 2006-12-19
HK1155747A1 (en) 2012-05-25
HUS1500046I1 (hu) 2017-05-29
FR15C0062I2 (fr) 2016-08-26
LTC1699784I2 (lt) 2017-09-11
CA2549062C (en) 2011-07-05
FR15C0062I1 (fr) 2015-10-30
US20130281492A1 (en) 2013-10-24
AU2004299413C1 (en) 2009-07-02
ATE514686T1 (de) 2011-07-15
CY1112445T1 (el) 2015-12-09
BRPI0417800B8 (pt) 2021-05-25
CN102516238B (zh) 2016-08-03
CY2015036I1 (el) 2016-06-22
JP4739229B2 (ja) 2011-08-03

Similar Documents

Publication Publication Date Title
HUS1500046I1 (hu) Új oxazolidinon-származékok
PH12014500092A1 (en) Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
HUT77602A (hu) Mikrobicid hatású fenil-oxazolidinon-származékok és alkalmazásuk gyógyszerkészítmények előállítására
WO2005014585A8 (en) Halogenated quinazolinyl nitrofurans as antibacterial agents
IL189017A0 (en) 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-effective agents
WO2009010765A3 (en) Lantibiotic-based compounds having antimicrobial activity
GEP20094834B (en) Macrolides, pharmaceutical compositions containing them and their use for treatment of bacterial infections
WO2005005398A3 (en) Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
EA200500283A1 (ru) Производные оксазолидинона как противомикробные средства
NZ545472A (en) 7-(4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl)quinolonecarboxylic acid derivative
EP1409464A4 (en) OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS
NO20070870L (no) Oksazolidinonforbindelser og sammensetninger og fremgangsmater relatert dertil
TW200740800A (en) Oxazolidinone compounds, and compositions and methods related thereto
WO2004056849A3 (en) Methanobactin: a copper binding compound having antibiotic and antioxidant activity isolated from methanotrophic bacteria
ATE254626T1 (de) Antibiotische caprazamycine und verfahren zu deren herstellung
WO2006046112A3 (en) Ketolide derivatives as antibacterial agents
WO2005121148A3 (en) Anti-bacterial and anti-cancer spiro beta-lactone/gamma-lactams
WO2006018682A3 (en) Oxazolidinone derivatives as antimicrobials
WO2008036420A3 (en) 9-(heteroaryl)-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents
WO2003068790A3 (en) Macrolide antibacterial compounds
WO2009116090A3 (en) Novel antimicrobials
ATE425984T1 (de) Trizyklische antibakterielle makrolidderivate
DE502005001193D1 (de) Hki10311129, neues antibiotikum, verfahren zu dessen herstellung und dessen verwendung
WO2003068791A3 (en) Macrolides with activity against methicillin-resistant staphylococcus aureus